Gritstone bio

Gritstone bio is a clinical-stage biotechnology company that leverages the EDGE (Epitope Discovery in Genetically Engineered context) AI platform to revolutionize immunotherapy. By 2026, Gritstone's technical architecture is recognized for its industry-leading precision in predicting which tumor-specific neoantigens will be presented on a patient’s HLA (Human Leukocyte Antigen) molecules. This is achieved through a deep learning neural network trained on a proprietary dataset of thousands of human tumor samples. The company's unique value proposition lies in its dual-platform approach: utilizing Chimpanzee Adenovirus (ChAd) for priming and self-amplifying mRNA (samRNA) for boosting immune responses. Unlike traditional mRNA, samRNA replicates within cells, allowing for significantly lower dosages while achieving sustained protein expression and potent CD8+ T cell induction. Their pipeline includes GRANITE, a fully personalized immunotherapy, and SLATE, an 'off-the-shelf' solution targeting shared neoantigens like KRAS mutations. Following their 2024-2025 strategic restructuring, the platform has matured into a licensing and partnership model for global pharmaceutical entities seeking to integrate high-fidelity epitope prediction into their vaccine development workflows.